Your shopping cart is currently empty

Bax inhibitor peptide V5 acetate (Bax inhibitor peptide V5 acetate(579492-81-2 free base)) is a Bax-mediated apoptosis inhibitor, used for cancer treatment.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $44 | In Stock | In Stock | |
| 2 mg | $61 | In Stock | In Stock | |
| 5 mg | $90 | In Stock | In Stock | |
| 10 mg | $132 | In Stock | In Stock | |
| 25 mg | $290 | In Stock | In Stock | |
| 50 mg | $478 | In Stock | In Stock | |
| 100 mg | $619 | In Stock | In Stock | |
| 200 mg | $809 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $143 | In Stock | In Stock |
| Description | Bax inhibitor peptide V5 acetate (Bax inhibitor peptide V5 acetate(579492-81-2 free base)) is a Bax-mediated apoptosis inhibitor, used for cancer treatment. |
| In vitro | Bax inhibitor peptide V5 (BIP-V5; 0-50 μM) decreases cell death in STF-cMyc cells but not in SW620 or NCI-H23 cells.[1]. V5 treatment upregulates expression of anti-apoptotic proteins Bcl-2 and XIAP by more than 3- and 11-fold and downregulates expression of apoptosis-inducing proteins Bax, Bad, and nuclear factor-κB-p65 by 10, 30, and nearly 50%, respectively[2]. |
| In vivo | Bax inhibitor peptide V5 (BIP-V5; 100 μM) significantly improves islet function following isolation and improves islet graft function following transplantation in mice model[2]. |
| Synonyms | Bax inhibitor peptide V5 acetate(579492-81-2 free base) |
| Molecular Weight | 646.85 |
| Formula | C29H54N6O8S |
| Smiles | O=C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)CC(C)C)=O)CCSC)[C@@H]1CCCN1C([C@H](C(C)C)N)=O.CC(O)=O |
| Relative Density. | no data available |
| Sequence | H-Val-Pro-Met-Leu-Lys-OH |
| Sequence Short | VPMLK |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 100 mg/mL (154.6 mM), Sonication is recommended. DMSO: 100 mg/mL (154.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | Saline: 100 mg/mL (154.6 mM), Heating is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.